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KEY POINTS: 
 
 Variation at 6p21.31, 6q23.3, 11q23.1, 16p11.2 and 20q13.12 influences risk of HL 
 Genetic predisposition implicates germinal centre dysfunction, disrupted T-cell function, and 
NF-κB activation in the pathogenesis of HL  
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ABSTRACT 
 
To further our understanding of inherited susceptibility to Hodgkin lymphoma (HL), we performed a 
meta-analysis of seven genome-wide association studies totalling 5,325 HL cases and 22,423 
controls. We identify five new HL risk loci at 6p21.31 (rs649775, P = 2.11 × 10-10), 6q23.3 (rs1002658, 
P = 2.97 × 10-8), 11q23.1 (rs7111520, P = 1.44 × 10-11), 16p11.2 (rs6565176, P = 4.00 × 10-8) and 
20q13.12 (rs2425752, P = 2.01 × 10-8). Integration of gene expression, histone modification and in 
situ promoter capture Hi-C data at the five new and 13 known risk loci implicates dysfunction of the 
germinal centre reaction, disrupted T-cell differentiation and function, and constitutive NF-κB 
activation as mechanisms of predisposition. These data provide further insights into the genetic 
susceptibility and biology of HL. 
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INTRODUCTION  
 
Hodgkin lymphoma (HL) comprises classical Hodgkin lymphoma (cHL) (∼95% of cases) and nodular 
lymphocyte predominant HL (NLPHL, ∼5% of cases)1. While cHL and NLPHL are defined by the 
Hodgkin and Reed-Sternberg (HRS) cell and the lymphocyte predominant (LP) cell respectively, both 
diseases are thought to arise from the malignant transformation germinal centre (GC) B-cell2,3. 
Furthermore, both cHL and NLPHL demonstrate a paucity of these neoplastic B-cells within a 
background of reactive inflammatory cells that includes large populations of CD4+ T-cells4,5. 
A viral or infectious agent has long been considered a major etiological factor for HL, with Epstein-
Barr virus (EBV) being the posited infectious agent6,7. However, the EBV genome is only identifiable 
in a minority of HL cases and epidemiological data supports a causal role for the virus in EBV-positive 
HL only8. Evidence for genetic susceptibility to HL is provided by the elevated familial risk as well as 
the high concordance between monozygotic twins9-11. More recently, genome-wide association 
studies (GWAS) have confirmed an HLA association for HL and have identified single nucleotide 
polymorphisms (SNPs) at 13 non-HLA loci influencing risk12,13.  
To gain further insight into HL susceptibility, we have conducted a meta-analysis of data from seven 
independent GWAS and report five new HL risk loci12-14. Integration of gene expression, histone 
modification and in situ promoter capture Hi-C data (PCHi-C) at the five new and the 13 known risk 
loci provides evidence for cell-type specificity in B- and T-cells and implicates dysfunction of the 
germinal centre reaction, disrupted T-cell differentiation and function, and constitutive NF-κB 
activation as mechanisms by which loci influence HL risk.  
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MATERIALS AND METHODS 
 
Ethics 
Collection of patient samples and associated clinico-pathological information was undertaken with 
written informed consent. Relevant ethical review boards approved the individual studies in 
accordance with the tenets of the Declaration of Helsinki (UK-GWAS MREC 03/1/096, German-GWAS 
University of Heidelberg 104/2004 and UK-GWAS-NSHLG MREC 09/MRE00/72). The diagnosis of HL 
in all cases was established in accordance with World Health Organisation guidelines. 
Genome-wide association studies 
We used GWAS data generated on three non-overlapping case–control series of Northern European 
ancestry, which have been the subject of previous analyses (Supplementary Tables 1 and 2)12. The 
UK-GWAS was based on 622 cases ascertained through the Royal Marsden Hospital National Health 
Service Trust Family History study during 2004–200815, and 5,677 controls from the UK Wellcome 
Trust Case Control Consortium 2 (WTCCC2)16. The German-GWAS comprised 1,001 cases ascertained 
by the German Hodgkin Study Group during 1998–2007, and 2,092 controls from the Heinz Nixdorf 
Recall (HNR) study17. The UK-NSHLG-GWAS utilised 1,717 cases ascertained through the NSHLG 
(http://www.public.ukcrn.org.uk) from 2010 to 201312. Controls comprised: (1) 2,976 cancer-free 
men recruited by the PRACTICAL Consortium—the UK Genetic Prostate Cancer Study (UKGPCS) 
(age < 65 years), a study conducted through the Royal Marsden NHS Foundation Trust and SEARCH 
(Study of Epidemiology & Risk Factors in Cancer), recruited via GP practices in East Anglia (2003–
2009), (2) 4,446 cancer-free women from across the UK via the Breast Cancer Association 
Consortium (BCAC). Details of the genotyping platform and quality control measures applied to each 
of the three GWAS have been described previously and are detailed in Supplementary Tables 3 and 
412,15,18,19. Briefly, individuals with a low call rate (< 95%) as well as all individuals evaluated to be of 
non-European ancestry, were excluded (Supplementary Figure 1). Eigenvectors for the GWAS data 
sets were inferred using smartpca (part of EIGENSOFT) by merging cases and controls with Phase III 
HapMap samples20. For apparent first-degree relative pairs, we excluded the control from a case–
control pair or the individual with the lower call rate (Supplementary Table 3). SNPs with a call rate 
< 95% were excluded as were those with a MAF < 0.01 or displaying deviation from Hardy–Weinberg 
equilibrium (HWE) (i.e., P < 10−6, Supplementary Table 4). GWAS data were phased with SHAPEIT321, 
and imputed to >10 million SNP using IMPUTE4 v1.022 and a merged reference panel consisting of 
data from 1000 Genomes Project (phase 3)23 and UK10K (EGAD00001000776)24. Imputation was 
 
Sud et al  
7 
 
conducted separately for each study from set of SNPs common to cases and controls. Poorly 
imputed SNPs (defined by an information measure < 0.80) were excluded. Tests of association 
between SNPs and HL were performed using logistic regression under an additive genetic model in 
SNPTESTv2.5.225. The adequacy of the case–control matching was evaluated using Q–Q plots of test 
statistics (Supplementary Fig. 2). The inflation factor λ1000 was based on the 90% least-significant SNP 
scaled to 1000 cases and 1000 controls.  
In addition to analysing data from these three GWAS, we made use of pre-processed association test 
statistics for HL risk from a meta-analysis of three additional GWAS (USC-IARC-UC-GWAS) comprising 
1,816 HL cases and 7, 879 contols13,26,27, and an analysis of 432 HL cases and 337,208 unaffected 
individuals14 from the UK Biobank accessed through the Global Biobank Engine. 
Meta-analysis 
Meta-analyses were performed under a fixed-effects model using META v1.725. Cochran’s Q-statistic 
to test for heterogeneity and the I2 statistic to quantify the proportion of the total variation due to 
heterogeneity were calculated; an I2 value ≥ 75% is considered to be characteristic of large 
heterogeneity28. Where the same controls were used in both the UK-GWAS and the USC-IARC-UC 
GWAS, these controls were excluded from the UK-GWAS association analysis. 
Cell culture 
L-428 HL cells were obtained from DSMZ and were cultured at 37°C in RPMI 1640 supplemented 
with 10% heat inactivated FBS (Thermo Scientific). Cell line identity was confirmed by STR-profiling. 
Cells were regularly tested for mycoplasma contamination (PromoCell, PK-CA91). 
ChIP-seq analysis  
L-428: ChIP-seq was performed on H3K27Ac and H3K4me3, for using antibodies obtained from 
Diagenode. Briefly, after cell lysing, sonication of nuclei was performed 293 (UCD-300, BioRuptor) to 
obtain 150-500bp fragments. ChIP reaction was performed on a Diagenode SX-8G IP-Star Compact 
using Diagenode automated Ideal Kit reagents (C01010011). Protein A beads were incubated for 10 
hours with 3-6μg of antibody and 2-4 million of sonicated cell lysate. ChIP samples were de-
crosslinked at 65°C for 4 hours and subsequently treated for 30 minutes with RNAse Cocktail and 
proteinase K. DNA was then purified (MiniElute PCR purification kit, Qiagen), followed by library 
preparation according to manufacture (HTP Illumina library preparation kit, KAPA Biosystems). 
Fourteen cycles of PCR were performed, followed by size selection for 200-400bp fragments and 
final library purification (GeneRead Size Selection kit, 301 Qiagen). ChIP libraries were sequenced 
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using HiSeq 2000 (Illumina) with 100bp single-ended reads. Generated raw reads were filtered for 
quality (Phred33 ≥ 30) and length (n ≥ 32), and adapter sequences were removed using Trimmomatic 
v0.2235. Reads passing filters were then aligned to the human reference (hg19) using BWA v0.6.1. 
Peak calls are obtained using MACS2 v 2.0.1.  
Histone modification data from primary blood cells: H3K27Ac and H3K4me3 data from >100 
samples from >30 cell types from the Blueprint Epigenome Consortium were analysed29. 
Cell-specificity analysis 
Overlap enrichment analysis of HL risk SNPs with H3K4me3 and H3K27Ac peaks was performed as 
described by Trynka et al30. Briefly, we evaluated whether the HL risk SNPs and SNPs in LD (r2 > 0.8) 
with the sentinel SNP, were enriched at H3K4me3 and H3K27Ac ChIP-seq peaks, in blood cells and 
the HRS cell line L-428 by a permutation procedure with 105 iterations.  
Promoter capture Hi-C  
In situ Hi-C libraries for L-428 were prepared as previously described31,32. Briefly, 25 million cells were 
fixed in 1% formaldehyde for 10 min. Cross-linked DNA was digested with HindIII (NEB, R0104) and 
chromatin ends were filled and marked with biotin-14-dATP (ThermoFisher, 19524-016). The 
resulting blunted ended fragments were ligated at 16°C in the nucleus with T4 DNA ligase (NEB, 
M0202) to minimise random ligation. DNA purified after crosslinking was reversed by proteinase K 
(Ambion, AM2546) treatment. DNA was sheared by sonication (Covaris, M220) and 200-650bp 
fragments selected. Biotin tag DNA was pulled down with streptavidin beads and ligated with 
Illumina paired end adapters (Illumina). Six cycles of PCR were performed to amplify libraries before 
capture. Promoter capture was based on 32,313 biotinylated 120-mer RNA baits (Agilent 
Technologies) targeting both ends of HindIII restriction fragments that overlap Ensembl promoters 
of protein-coding, non-coding, antisense, snRNA, miRNA and snoRNA transcripts (Supplementary 
Data). After library enrichment, a post-capture PCR amplification step was carried out using 6 
amplification cycles. Hi-C and PCHi-C libraries were sequenced using HiSeq 2000 technology 
(Illumina). Reads were aligned to the GRCh37 build using Bowtie2 v2.2.633 and identification of valid 
di-tags was performed using HiCUP v0.5.934. To declare significant contacts, HiCUP output was 
processed using CHiCAGO v1.1.835. Data from three independent biological replicates were 
combined to define definitive set of contacts. Publicly accessible PCHi-C data generated in B- and T-
cell populations were downloaded from the Open Science Framework36.  
Chromatin interactions relevant to HL risk loci were defined as contacts overlapping with HL risk 
SNPs and SNPs in LD (r2 >0.8 with the sentinel SNP), with promoters within a 2Mb window of the 
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sentinel SNP, and with a score ≥ 5.035. Plotting of HL association data and chromatin contacts was 
performed using visPIG37. 
Expression quantitative trait loci analysis 
An analysis of associations between the SNPs (r2 > 0.8) at each locus and tissue-specific changes in 
gene expression was performed using summary statistics from three publicly available resources: (i) 
lymphobastoid cell line (LCL) expression from the MuTHER (n = 825) consortium38; (ii) LCL expression 
from the GTEx consortium (n = 114)39; (iii) CD4+ and CD8+ T-cells from 313 individuals40. Statistical 
significance was assigned after correcting for the number of probes at each locus (microarray) or the 
number of transcripts at each locus (RNA-seq) for each expression dataset. 
Genetic correlation with infection 
To estimate the genetic correlation between specific infections and all HL, and NSHL and MCHL 
subtypes41, we used LD score regression. Summary statistics for self-reported infectious diseases 
from over 200,000 participants in 23andMe included42: chickenpox, shingles, cold sores, 
mononucleosis, mumps, hepatitis B, plantar warts, positive tuberculosis test results, streptococcus 
throat infection, scarlet fever, pneumonia, bacterial meningitis, yeast infections, urinary tract 
infections, tonsillectomy, childhood ear infections, myringotomy, measles, hepatitis A, rheumatic 
fever, common colds, rubella, and chronic sinus infection. 
Mendelian randomisation 
We performed two-sample MR using SNPs associated with specific infection-related traits as IVs. 
SNPs associated with each of the infection-related traits at genome-wide significance (i.e. P ≤ 5.0 × 
10−8) were used as IVs42. We analysed infection-related traits for which >2 SNPs had been shown to 
be associated with the specific infection (tonsillectomy, mumps infection, childhood ear infection 
and yeast infections). To avoid co-linearity between SNPs for each trait, we excluded SNPs that were 
correlated (i.e. r2 value of ≥ 0.01) within each trait, and only considered the SNPs with the strongest 
effect on the trait for use as IVs. Where data on an IV was not present in the outcome trait, a proxy 
was utilised (r2>0.6). Details of the IVs used are detailed in Supplementary Data. For each SNP, we 
recovered the chromosome position, risk allele, association estimates (per-allele log-OR) and 
standard errors. The allele that was associated with increased risk of the exposure was considered 
the effect allele. The odds ratios (OR) of HL, NSHL and MCHL per unit of standard deviation 
increment for each infection-related trait, were estimated using the ‘Mendelian randomisation’ R 
package43. Given that traits analysed are binary outcomes, the maximum likelihood method was 
 
Sud et al  
10 
 
employed with the resulting causal effect estimate representing the odds for HL risk per unit 
increase in the log OR for infection-related trait. 
 
Sud et al  
11 
 
RESULTS 
 
Association analysis 
We analysed summary level GWAS data generated on HL cases and controls of European ancestry12 
from three sources (Supplementary Tables 1-4): (1) two GWAS of UK cases and controls and one 
GWAS of German cases and controls, totalling 3,077 cases and 14,546 controls (Discovery GWAS)12; 
(2) the Stanford Global Biobank Engine, an analysis of 432 HL cases from the UK Biobank14 and (3) a 
meta-analysis of three published HL GWAS totalling 1,816 HL cases and 7,879 controls (USC-IARC-
UC-GWAS)13,26,27.  
In a meta-analysis of data from the seven studies, we identified new genome-wide significant 
associations for HL (Figure 1 and Table 1), at 6p21.31 (rs649775, P = 2.11 × 10-10, marking ITPR3-
UQCC2-IP6K3), 6q23.3 (rs1002658, P = 2.97 × 10-8, marking OLIG3-TNFAIP3), 11q23.1 (rs7111520, P = 
1.44 × 10-11, marking POU2AF1), 16p11.2 (rs6565176, P = 4.00 × 10-8, marking MAPK3-CORO1A) and 
20q13.13 (rs2425752, P = 2.01 × 10-8, marking NCOA5-CD40). In addition, we identified a promising 
association at 1p13.2 (rs2476601, P = 4.20 × 10-7, marking PTPN22). 
The bimodal incidence of HL and the higher rate of nodular sclerosis Hodgkin lymphoma (NSHL) and 
EBV-negative HL in young adults suggest differences in the etiology of HL subtypes8. Case-only 
analysis however provided no evidence for an age or histological subtype association for the five 
new risk SNPs. (Supplementary Tables 5 and 6). 
 
Cell specificity of associations  
Trynka et al., have recently shown that chromatin marks highlighting regulatory regions, overlap 
with phenotype-associated variants in a cell-type specific manner30. To examine for cell-type 
specificity of the five new and 13 known HL risk loci we analysed H3K4me3 and H3K27Ac chromatin 
marks which annotate regulatory regions, in over 125 samples from 38 hematopoietic cell types 
from BLUEPRINT29,30 and the HRS cell line L-428. The H3K27Ac histone mark is predominantly 
associated with enhancers and of all the histone marks demonstrates the greatest enrichment of 
promoter interacting regions36. The H3K4me3 histone mark is predominantly associated with 
promoters and transcribed regions, and has previously been shown to be the most phenotypically 
cell-type specific30,44. Cell types showing the strongest enrichment of risk SNPs at H3K4me3 marks 
were CD4+ T-cells from venous blood (P = 2.9 × 10-3), CD3- CD4+ CD8+ positive thymocytes (P = 5.7 × 
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10-3) and tonsillar derived germinal centre B-cell (P = 6.3 × 10-3) (Supplementary Table 7). Cell types 
with the strongest enrichment of risk SNPs at H3K27Ac marks were CD8+ T-cells from venous blood 
(P = 3.0 × 10-4), CD3+ CD4+ CD8+ thymocytes (P = 5.6 × 10-4), CD4+ thymocytes (P = 2.7 × 10-3) and L-
428 (P = 7.9 × 10-3) (Supplementary Table 8). Based on the co-localisation of variants with active 
chromatin marks, we calculated an enrichment scores for each genetic association (Figure 2)30. High 
SNP regulatory scores were also shown in T-cells cells at 3p24.1, 6q22.33, 6q23.3 and 10p14 risk loci, 
in B-cells at 2p16.1, 3q28, 8q24.21, 11q23.1 and 20q13.12 risk loci and in HRS cells at 3p24.1, 
5q31.1, 6q22.33, 6q23.3, 10p14, 13q34 16p13.13 and 20q13.12. 
 
Identification of candidate target genes at HL risk loci 
Most GWAS loci map to non-coding regions of the genome and influence gene regulation45. Hence, 
to gain insight into the biological mechanisms for the associations at the 5 new and 13 known HL risk 
loci, we first performed expression quantitative trait locus (eQTL) analysis on expression data in B-
cell lymphoblastoid cell lines (LCL) and in CD4+ and CD8+ T-cells. We identified eQTLs in LCL at 
6p21.31 (ITPR3), 6q23.3 (AHI1, ALDH8A1), 10p14 (GATA3), 11q23.1 (COLCA1, COLCA2), 13q34 
(UPF3A, CDC16), 16p13.13 (SOCS1), 16p11.2 (MAPK3, BOLA2) and 20q13.12 (CD40, WFDC10B); in 
CD4+ T-cells at 6q23.3 (AHI1) and 13q34 (CDC16); and in CD8+ T-cell at 3p24.1 (EOMES), 6q23.3 
(AHI1) and 13q34 (CDC16) (Table 2 and Supplementary Tables 9 and 10). 
Chromatin looping interactions between enhancer elements and promotors are central to regulation 
of gene expression46. To link risk loci to candidate target genes we analysed PCHi-C data. Firstly, we 
examined physical interactions at genomic regions annotated by HL risk loci (including variants with 
an r2 > 0.8) using publicly accessible PCHi-C in naïve and total B-cells, as well as CD4+ and CD8+ T-
cells36. Secondly, we generated and analysed PCHi-C data for the HRS cell line L-428. We observed 
concordance between H3K27Ac peaks and chromatin contacts in B-, T- and HRS cells for specific HL 
risk loci. Notable chromatin contacts were found in the B-lineage at 2p16.1 (REL), 6p21.31 (BAK1), 
8q24.21 (MYC, PVT1), 13q34 (RASA3), 16p.13.13 (RMI2) and 20q13.12 (CD40); in the T-lineage at 
3p24.1 (EOMES, AZI2), 6p21.31 (BAK1), 6q22.33 (THEMIS, PTPRK), 6q23.3 (MYB), 13q34 (RASA3) and 
16p13.13 (SOCS1, RMI2); and in L-428 at 3p24.1 (AZI2, CMC1), 6q23.3 (MYB), 6q23.3 (TNFAIP3) and 
16p13.13 (SOCS1, RMI2) (Table 2, Supplementary Figure 3 and Supplementary Data).  
 
Shared susceptibility with infection 
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The association between EBV with HL, coupled with epidemiological reports of HL also being 
associated with non-EBV infections47-50, suggests shared susceptibility a priori. Support for such an 
assertion is provided by a recent report implicating a number of the HL loci, including 6q23.3, 
16p11.2 and 20q13.12, as well as the HLA region, as determinants of risk of infection42. 
To investigate co-heritability between HL and susceptibility to infection, we implemented cross-trait 
LD score regression41. Using summary-level GWAS data, we estimated genetic correlations between 
HL and over 20 self-reported infections in 200,000 23andMe participants42. Overall no statistically 
significant correlation was shown between any specific infection and HL, NSHL or mixed cellularity 
Hodgkin lymphoma (Supplementary Table 11). Following on from this, for infections with greater 
than two genetically defined instrumental variables (IVs), we performed a Mendelian randomisation 
(MR) analysis to identify a potential causal relationship with HL. For tonsillectomy, yeast infections 
and childhood ear infections, no statistically significant associations were demonstrated 
(Supplementary Tables 12). A nominally significant positive association between self-reported 
mumps infection and HL was found (P = 0.04), however this was not significant after correction for 
multiple testing. 
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DISCUSSION 
 
By utilising publicly available summary statistics we have increased the power of our study allowing 
us to identify five new HL risk loci, thus bringing the total number of HL risk loci to 18. Whilst our 
reliance on such data has restrained our ability to examine subtype-specific effects, it is likely that 
the newly described risk loci have generic effects on HL susceptibility as with the known risk loci at 
5q31.1 and 19p13.312.  
At the new and known HL risk loci, we observed an enrichment of active regulatory regions in 
germinal centre B-cells, CD4+ thymocytes, CD4+ T-cells and CD8+ T-cells. Furthermore, whilst some 
HL risk loci locate to H3K27Ac peaks in both B- and T-cells, a number display lineage-specificity. 
Motivated by this finding, we have utilised PCHi-C and gene expression data in these cell types to 
identify targets subject to regulatory control by HL risk SNPs. While in part speculative, and requiring 
functional validation, integrating proximity, cell specificity of risk loci, gene expression and PCHi-C 
data, our analyses highlight three biological processes and their associated genes as a basis of HL 
susceptibility (Table 2): the germinal centre reaction (2p16.1, REL51; 3q28, BCL6 and mir-2852,53; 
6p21, HLA54; 6q23.3, MYB55; 8q24.21, MYC56; 11q23.1, POU2AF157; 16p11.2, MAPK358; 19p13.3, 
TCF359; 20q13.12, CD40)60,61, T-cell differentiation and function (3p24.1, EOMES62; 5q31,1, IL1363; 
6q22.33, PTPRK and THEMIS64,65; 6q23.3, MYB66; 6q23.3, AHI167; 10p14, GATA368; 16p13.1, SOCS1 
and CLEC16A69,70; 16p11.2, MAPK3 and CORO1A71,72) and constitutive NF-κB activation (2p16.1, 
REL73; 3p24.1, AZI274; 6q23.3, TNFAIP375; 20q13.12, CD4076,77).   
Our findings extend the relationship between germline genetics and tumor biology45, as evidenced 
by enrichment of active chromatin marks for HL risk loci in L-428, and the finding of many of the 
target genes for HL GWAS associations are subject to somatic alterations in HRS cells, namely REL78, 
TNFAIP3 and SOCS179-81. The composite cellular basis of the HL tumor represents a pre-eminent 
example of the importance of the cellular microenvironment for the development of cancer. Hence, 
it is entirely conceivable that some of the HL risk loci may impact on the development of the B-cell 
tumor indirectly. Support for such an assertion is the observation of T-cell specificity as well as the 
finding of an eQTL at 3p24.1 (EOMES) in CD8+ T-cells. Notably, EomesHi T-betLo PD-1Hi CD8+ T-cells 
are considered to delineate a key subset of exhausted CD8+ T-cells82,83 which may contribute to an 
immunosuppressive tumor microenvironment and is a feature of peripheral blood T-cells in HL84. 
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There are a number of reasons for the observed lack of concordance between the PCHi-C and eQTL 
analysis at risk loci. Firstly, the resolution of the Hi-C library using HindIII, a 6-base pair cutter, is 
approximately 10kb. As such, we are unable to detect concordant chromatin contacts at risk loci 
which influence the expression of genes located <10kb. Secondly, it is recognised that the range at 
which gene expression is perturbed to influence disease risk, may be narrow and as such may not be 
detected by an eQTL analysis. Finally, given the risk loci are likely to act in specific cell populations, 
and our expression data is limited by broad B- and T-cell populations, it is possible that we have not 
captured the cell type to analyse expression. As such we would view both methods as 
complimentary in identifying target genes. 
The established association between EBV and risk of HL, coupled with other epidemiological 
observations provides strong a priori evidence for infection being a major etiological risk factor for 
HL. While our MR analysis failed to implicate a causal relationship with any of the self-reported 
infection traits, we acknowledge that our study had limited power. It is, however, possible that 
pleiotropism between the 6p21.1, 6q23.3, 16p11.2 and 20q13.12 risk loci for HL and tonsillectomy is 
consistent with some form of a shared biological basis. This is intriguing since tonsillectomy has 
previously been linked to HL in some epidemiological observational studies47. 
In conclusion, our study provides further evidence for inherited susceptibility to HL and support for 
cell-type specificity at HL risk loci. Furthermore, through the integration of gene expression, histone 
modification and in situ PCHi-C data, our data highlights dysfunction of the germinal centre reaction, 
perturbed T-cell function and constitutive NF-κB activation as mechanisms by which genetic risk loci 
influence HL pathogenesis.  
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Table 1: Summary results for newly identified Hodgkin lymphoma risk loci. Freq, frequency; bp, base pair; OR, odds ratio; CI, confidence interval; I
2
 proportion of the total 
variation due to heterogeneity.
¥
 Summary statistics from 1,200 cHL patients and 6,417 controls
27
. †Genes at each risk locus are given for identification purposes only and 
does not necessarily indicate biological functionality. 
 
 
 
 Risk  Discovery GWAS meta-analysis UK Biobank USC-IARC-UC-GWAS Meta-analysis 
Locus Nearest genes† allele (freq) Position (hg19, bp) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value OR (95% CI) I2 (%) Phet 
1p13.2, rs2476601 PTPN22 A (0.12) 114377568 3.92 × 10
-3
 1.15 (1.04-1.26) 3.21 × 10
-4
 1.42 (1.17-1.72) 3.70 × 10
-3
 1.24 (1.07-1.44)
¥
 4.20 × 10
-7
 1.21 (1.12-1.30) 20 0.29 
6p21.31,  rs649775 
ITPR3- UQCC2-
IP6K3 
A (0.11) 33684313 4.00 × 10-6 1.25 (1.14-1.38) - - 8.22 × 10-6 1.36 (1.19-1.55) 2.11× 10-10 1.29 (1.19-1.40) 0 0.54 
6q23.3,  rs1002658 OLIG3-TNFAIP3 T (0.18) 137981584 3.86 × 10-6 1.19 (1.11-1.28) - - 2.15 × 10-3 1.18 (1.06-1.31) 2.97 × 10-8 1.19 (1.12-1.26) 0 0.53 
11q23.1, rs7111520 POU2AF1 A (0.70) 111249611 4.33 × 10
-7
 1.17 (1.10-1.24) - - 4.39 × 10
-6
 1.24 (1.13-1.35) 1.44 × 10
-11
 1.19 (1.13-1.25) 0 0.68 
16p11.2, rs6565176 MAPK3-CORO1A T (0.48) 30174926 8.64 × 10
-6
 1.14 (1.08-1.21) 3.44 × 10
-4
 1.28 (1.10-1.23) - - 4.00 × 10
-8
 1.16 (1.10-1.22) 0 0.46 
20q13.12, rs2425752 NCOA5-CD40 T (0.23) 44702120 2.23 × 10-4 1.13 (1.06-1.20) 2.94 × 10-4 1.30 (1.12-1.50) 3.77 × 10-3 1.14 (1.09-1.20) 2.01 × 10-8 1.15 (1.10-1.21) 56 0.06 
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Table 2: Integration of expression quantitative trait loci, histone modification, promoter capture Hi-C data at non-HLA Hodgkin lymphoma risk loci to identify candidate 
causal genes at Hodgkin lymphoma risk loci. bp, base pair; cHL, classical Hodgkin lymphoma; NSHL; nodular sclerosis Hodgkin lymphoma; SNP, single nucleotide 
polymorphism; LCL, lymphoblastoid cell lines; LD, linkage disequilibrium. 
¥
SNPs (r
2 
< 2.5 kilobases from ChIP-seq peak).  
 
Locus Sentinel SNP Position 
(bp, hg19) 
Gene(s) 
in LD 
block 
Coding 
variant(s) 
Promotor
/UTR 
variant(s) 
Expression 
quantitative 
trait loci in LCL 
Expression 
quantitative 
trait loci in T-
cell 
H3K27Ac histone peak¥ Hi-C 
contact(s) in 
naïve or 
total B-cells 
Hi-C 
contact(s) in 
T-cells 
Hi-C 
contact(s) in 
HRS cell 
Evidence of 
perturbation in 
HL 
Candidate biological mechanism 
2p16.1 rs2420518 
 
61054980      Naïve B-cell REL REL  REL85 Constitutive NF-κB activation (REL)73 
 
Altered B-cell differentiation and 
germinal centre reaction (REL)
51
 
3p24.1 rs3806624 27764623 EOMES  EOMES 
(3'-UTR) 
 EOMES (↑) 
(CD8+) 
Effector memory CD8+ T-cell 
Plasma cell 
L-428 
AZI2, CMC1, 
NEK10, 
OXSM, 
NGLY1, 
ZCWPW2 
EOMES, 
AZI2, CMC1, 
NEK10, 
OXSM, 
NGLY1, 
ZCWPW2 
AZI2 
CMC1 
 
EOMES86 
 
 
 
Exhausted CD8 T-cell phenotype 
(EOMES)62,82,83 
 
Constitutive NF-κB activation (AZI2)74 
 
3q28 rs4459895 187954414 LPP     CD38- naïve B-cell 
Naïve B-cell 
Germinal centre B-cell 
L-428 
   BCL687 Dysfunction of B-cell germinal centre 
reaction (BCL6, mir-28)52,53 
 
5q31.1 rs848 131996500 IL-13 (p.Gln144Arg) 
 
IL-13 
(3'-UTR) 
  L-428    IL-1388 Altered CD4+ T-cell function (IL-13)63 
6p21.31 rs649775 33684313 ITPR3 
UQCC2 
IP6K3 
 IP6K3  
(3'-UTR) 
ITPR3 (↓)  CD4+ T-cell 
CD8+ T-cell 
Effector memory CD8+ T-cell 
Naïve B-cell 
Class switched memory B-cell 
BAK1, 
SYNGAP1, 
GGNBP1, 
LINC00336 
BAK1, 
GRM4, 
SYNGAP1, 
KIFC1, CUTA, 
PHF1, 
GGNBP1, 
LINC003336 
  Altered B-cell differentiation (ITPR3)89 
 
6q22.33 rs9482849 128288536 PTPRK 
 
    CD4+ T-cell 
Central memory CD4+ T-cell 
CD8+ T-cell 
Effector memory CD8+ T-cell 
L-428 
PTPRK 
THEMIS 
  PTPRK90 Altered T-cell differentiation (PTPRK, 
THEMIS)64,65 
 
6q23.3 rs9402684 135419305 HBS1L     CD3- CD4+ CD8+ thymocyte 
CD3+ CD4+ CD8+ thymocyte 
CD4+ T-cell 
Central memory CD4+ T-cell 
CD8+ T-cell 
Effector memory CD8+ T-cell 
Germinal centre B-cell 
Plasma cell 
L-428 
MYB 
 
 MYB 
 
 Altered T-cell differentiation (MYB)66,91 
 
 
Altered B-cell differentiation and 
germinal centre reaction (MYB)55 
 
6q23.3 rs6928977 135626348 AHI1 
 
  AHI1 (↑) 
ALDH8A1 (↑) 
AHI1 (CD4+ and 
CD8+)  (↑) 
CD3+ CD4+ CD8+ thymocyte     Altered T-cell differentiation (AHI1)67 
6q23.3 rs1002658 137981584      L-428 RP11-
204P2.3 
 TNFAIP3 
 
TNFAIP379 
 
Constitutive NF-κB activation 
(TNFAIP3)75 
8q24.21 rs34748721 129195943      Naïve B-cell 
Class switched memory B-cell 
CASC11, 
MYC, PVT1, 
RNU1-106P, 
MIR1207 
  MYC92 
 
Dysfunction of B-cell germinal centre 
reaction (MYC)56,77 
10p14 rs2388486 8099021 GATA3   GATA3(↓)  CD3- CD4+ CD8+ thymocyte 
CD3+ CD4+ CD8+ thymocyte 
CD4+ T-cell 
CD8+ T-cell 
   GATA393 Altered T-cell differentiation (GATA3)68 
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Effector memory CD8+ T-cell 
Germinal centre B-cell 
10p14 rs3781093 8101927 GATA3   GATA3 (↓)  CD4+ T-cell 
CD8+ T-cell 
   GATA3 Altered CD4+ T-cell differentiation 
(GATA3)68 
 
Altered B-cell differentiation (GATA3)94 
11q23.1 rs7111520 111249611 POU2AF1   COLCA1 (↑) 
COLCA2 (↑) 
 CD4+ T-cell 
Central memory CD4+ T-cell 
CD8+ T-cell 
CD38- B-cell 
CD38- naïve B-cell 
Naïve B-cell 
Germinal centre B-cell 
Unswitched memory B-cell 
Class switched memory B-cell 
Plasma cell 
FDX1 FDX1, 
PPP3R1B, 
ALG9, 
FDXACB1, 
DIXDC1 
 POU2AF195 Dysfunctional germinal centre reaction 
(POU2AF1)57 
 
13q34 rs112998813 115059729 UPF3A   CDC16 (↑) 
UPF3A (↓) 
CDC16 (CD4+ 
and CD8+) ↑) 
CD4+ T-cell 
Central memory CD4+ T-cell 
CD8+ T-cell 
Effector memory CD8+ T-cell 
CD38- naïve B-cell 
Naïve B-cell 
Germinal centre B-cell 
Unswitched memory B-cell 
Class switched memory B-cell 
Plasma cell 
 RASA3, 
TMEM255B, 
GASA6 
 CDC1686 
 
Disrupted cell cycle regulation (CDC16)96 
 
Dysfunction of mRNA surveillance 
(UPF3A)97 
 
16p13.13 rs34972832 11198938 CLEC16A   SOCS1 (↑)  CD4+ T-cell 
Central memory CD4+ T-cell 
CD8+ T-cell 
Effector memory CD8+ T-cell 
Naïve B-cell 
Germinal centre B-cell 
Class switched memory B-cell 
Plasma cell 
L-424 
RMI2 SOCS1, 
RMI2, 
PRM2, 
PRM3, 
TNP2, 
HNRNPCP4 
SOCS1 
RMI2 
SOCS181 T-cell dysfunction (SOCS1)69. 
 
Altered T-cell differentiation (CLEC16A)70 
 
B-cell dysfunction (CLEC16A)98 
 
 
Genomic instability (RMI2)99 
16p11.2 rs6565176 30174926 CORO1A  CORO1A 
(5’-UTR) 
MAPK3 (↓) 
BOLA2 (↓) 
 
 CD4+ T-cell 
CD8+ T-cell 
Effector memory CD8+ T-cell 
Naïve B-cell 
Class switched memory B-cell 
   MAPK3100 
CORO1A101 
T-cell dysfunction (CORO1A and 
MAPK3)64,71,72 
 
Dysfunction of B-cell germinal centre 
reaction (MAPK3)58,102,103 
19p13.3 rs2012125 1630341 TCF3A     CD38- B-cell 
Naïve B-cell 
Class switched memory B-cell 
    Dysfunction of B-cell germinal centre 
reaction (TCF3A)104 
 
20q13.12 rs2425752 44702120 NCOA5 
CD40 
  CD40 (↓) 
WFDC10B (↑) 
 Central memory CD4+ T-cell 
CD8+ T-cell 
Effector memory CD8+ T-cell 
Naïve B-cell 
Germinal centre B-cell 
L-428 
CD40 TP53RK  CD40105 Dysfunctional germinal centre reaction 
(CD40)54,61 
 
Constitutive NF-κB activation (CD40)76,77 
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FIGURES 
Figure 1: Genome-wide meta-analysis P values of Hodgkin’s lymphoma risk (–log10P, y axis) plotted against their chromosomal positions (x axis). Novel 
HL risk loci and candidate gene are in orange. 
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Figure 2: Heat map of SNP scores for H3K27Ac and H3K4me3 at each Hodgkin lymphoma risk locus. SNP score calculated as per Trynka et al.30 For each 
SNP at a given locus, the score represents the height of the closest ChIP-seq peak divided by the distance to the summit in each each cell line, normalised 
across all immune cell types. Thus, a SNP within a chromatin mark that is active in only one cell type will have a high score of 1 (red) in that cell type and 0 
(white) in others. In contrast, a SNP close to chromatin marks that are not cell type specific will have similarly modest scores across cell types. Genes at 
each risk locus are given for identification purposes only and do not necessarily indicate biological functionality.  
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